Intravenous Immunoglobulin Market: Global Industry Analysis and forecast (2022-2029)


Intravenous Immunoglobulin Market is expected to grow at a CAGR of 5% during the forecast period. global Intravenous Immunoglobulin Market is expected to reach US$ 19.44 Bn. by 2029.

Intravenous Immunoglobulin MarketTo know about the Research Methodology :- Request Free Sample Report

Intravenous Immunoglobulin Market Drivers and Restrains:

Immunoglobulins are the glycoprotein molecules produced by the plasma or the white blood cells in response to antigens, which are foreign to the immune system. They are obtained from blood by fractionation process and purified for therapeutic and nontherapeutic applications. This, coupled with the proven efficiency of the immunoglobulins as an effective treatment option for a number of immune diseases and the lack of training. Different classes of immunoglobulin such as IgG, IgA, and IgM are used for the treatment of several immunological and neurological diseases.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

The intravenous immunoglobulin market has driven by factors like rising incidence of immunodeficiency diseases, increasing adoption of immunoglobulin replacement therapy and rising geriatric population. However, stringent regulations pertaining to production and approval and cost Intensive nature of immunoglobulin replacement therapy are major restraining factored the market growth at global level.

Intravenous Immunoglobulin Market Segmentation Analysis:

Based on the indication, the intravenous immunoglobulin market has been segmented into chronic inflammatory demyelinating polyneuropathy (CIDP), Primary humoral immunodeficiency, Idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, Myasthenia gravis, Multifocal motor neuropathy (MMN), Kawasaki disease, Hypogammaglobulinemia, Chronic lymphocytic leukemia. The hypogammaglobulinemia segment was the highest contributor to the market in 2021, and is expected to maintain its dominance throughout the forecast period. This is attributed to the significant rise in the incidence of hypogammaglobulinemia disorder around the world over the years. For instance, hypogammaglobulinemia is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs). Its incidence rate is nearly xx% per xx population yearly, globally.

Intravenous Immunoglobulin Market Regional Insights:

Geographically, the Intravenous Immunoglobulin market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share xx% of the Intravenous Immunoglobulin market in 2021 owing to superior health care infrastructure, strong regional economics, easy access to advanced technology, and rise in reimbursement initiatives. According to the Immune Deficiency Foundation (IDF), almost xx people per xx in the U.S. suffer from primary immunodeficiency and there are over xx million undiagnosed cases in the country.

The intravenous immunoglobulin market in Asia Pacific is witnessing strong growth, attributed to increase in inpatient population and rise in usage of IVIG by end-users such as hospitals and clinics. Emerging countries in Asia Pacific such as China and India are poised to be the most promising markets for IVIG in the near future. Large underserved patient population, extensive development of health care infrastructure, and rise in emphasis on research and development in the health care sector are major driving factors of the market growth.

Intravenous Immunoglobulin Market Competitive landscape

Major Key players operating in this market are Baxter international Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG. Manufacturers in the intravenous immunoglobulin are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present comprehensive analysis of intravenous immunoglobulin market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding intravenous immunoglobulin market dynamics, structure by analyzing the market segments, and project the intravenous immunoglobulin market size. Clear representation of competitive analysis of key players by product type, price, financial position, product portfolio, growth strategies, and regional presence in the intravenous immunoglobulin market make the report investor’s guide.

Intravenous Immunoglobulin Market Scope: Inquire before buying


Intravenous Immunoglobulin Market, by Indication:

• Chronic inflammatory demyelinating Polyneuropathy (CIDP)
• Primary humoral immunodeficiency
• Idiopathic thrombocytopenic purpura (ITP)
• Guillain-Barre syndrome
• Myasthenia gravis
• Multifocal motor neuropathy (MMN)
• Kawasaki disease
• Hypogammaglobulinemia
• Chronic lymphocytic leukemia

Intravenous Immunoglobulin Market, by End User:

• Hospitals
• Clinics
• Home Care

Intravenous Immunoglobulin Market, by Region:

• Asia Pacific
• North America
• Europe
• Latin America
• Middle East Africa

Intravenous Immunoglobulin Market, Key Players:

• Baxter international Inc.
• CSL Ltd.
• Grifols S.A
• Octapharma AG
• Kedrion Biopharma Inc.
• LFB group
• Biotest AG
• China Biologics Products, Inc.
• Takeda Pharmaceuticals
• Bayer Healthcare
• Hualan Biological Engineering Inc.
• Omrix Biopharmaceuticals Ltd.
• Behring GmbH
• Shanghai RAAS Blood Products Co., Ltd.
• Option Care Enterprises, Inc.
• ADMA Biologics, Inc.
• BioScrip, Inc.
• Bio Products Laboratory Limited
• ABEONA THERAPEUTICS
• BDI Pharma
• Biotest AG

Frequently Asked Questions:

1. Which region has the largest share in Global Intravenous Immunoglobulin Market?
Ans: North America region holds the highest share in 2021.

2. What is the growth rate of Global Intravenous Immunoglobulin Market?
Ans: The Global Intravenous Immunoglobulin Market is growing at a CAGR of 5% during forecasting period 2022-2029.

3. What is scope of the Global Intravenous Immunoglobulin market report?
Ans: Global Intravenous Immunoglobulin Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Intravenous Immunoglobulin market?
Ans: The important key players in the Global Intravenous Immunoglobulin Market are – Baxter international Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., Takeda Pharmaceuticals, Bayer Healthcare, Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd., Behring GmbH, Shanghai RAAS Blood Products Co., Ltd., Option Care Enterprises, Inc., ADMA Biologics, Inc., BioScrip, Inc., Bio Products Laboratory Limited, ABEONA THERAPEUTICS, BDI Pharma, and Biotest AG

5. What is the study period of this market?
Ans: The Global Intravenous Immunoglobulin Market is studied from 2021 to 2029. 




Intravenous Immunoglobulin Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Intravenous Immunoglobulin Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
4.8. Patent Registration

5. Supply Side and Demand Side Indicators
6. Global Intravenous Immunoglobulin Market Analysis and Forecast
6.1. Global Intravenous Immunoglobulin Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Intravenous Immunoglobulin Market Analysis and Forecast, by Indication
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Intravenous Immunoglobulin Market Value Share Analysis, by Indication
7.4. Global Intravenous Immunoglobulin Market Size (US$ Bn) Forecast, by Indication
7.5. Global Intravenous Immunoglobulin Market Analysis, by Indication
7.6. Global Intravenous Immunoglobulin Market Attractiveness Analysis, by Indication

8. Global Intravenous Immunoglobulin Market Analysis and Forecast, by End User
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Intravenous Immunoglobulin Market Value Share Analysis, by End User
8.4. Global Intravenous Immunoglobulin Market Size (US$ Bn) Forecast, by End User
8.5. Global Intravenous Immunoglobulin Market Analysis, by End User
8.6. Global Intravenous Immunoglobulin Market Attractiveness Analysis, by End User

9. Global Intravenous Immunoglobulin Market Analysis, by Region
9.1. Global Intravenous Immunoglobulin Market Value Share Analysis, by Region
9.2. Global Intravenous Immunoglobulin Market Size (US$ Bn) Forecast, by Region
9.3. Global Intravenous Immunoglobulin Market Attractiveness Analysis, by Region

10. North America Intravenous Immunoglobulin Market Analysis
10.1. Key Findings
10.2. North America Intravenous Immunoglobulin Market Overview
10.3. North America Intravenous Immunoglobulin Market Value Share Analysis, by Indication
10.4. North America Intravenous Immunoglobulin Market Forecast, by Indication
10.4.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
10.4.2. Primary humoral immunodeficiency
10.4.3. Idiopathic thrombocytopenic purpura (ITP)
10.4.4. Guillain-Barre syndrome
10.4.5. Myasthenia gravis
10.4.6. Multifocal motor neuropathy (MMN)
10.4.7. Kawasaki disease
10.4.8. Hypogammaglobulinemia
10.4.9. Chronic lymphocytic leukemia
10.5. North America Intravenous Immunoglobulin Market Value Share Analysis, by End User
10.6. North America Intravenous Immunoglobulin Market Forecast, by End User
10.6.1. Hospitals
10.6.2. Clinics
10.6.3. Home Care
10.7. North America Intravenous Immunoglobulin Market Value Share Analysis, by Country
10.8. North America Intravenous Immunoglobulin Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.9. North America Intravenous Immunoglobulin Market Analysis, by Country
10.10. U.S. Intravenous Immunoglobulin Market Forecast, by Indication
10.10.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
10.10.2. Primary humoral immunodeficiency
10.10.3. Idiopathic thrombocytopenic purpura (ITP)
10.10.4. Guillain-Barre syndrome
10.10.5. Myasthenia gravis
10.10.6. Multifocal motor neuropathy (MMN)
10.10.7. Kawasaki disease
10.10.8. Hypogammaglobulinemia
10.10.9. Chronic lymphocytic leukemia
10.11. U.S. Intravenous Immunoglobulin Market Forecast, by End User
10.11.1. Hospitals
10.11.2. Clinics
10.11.3. Home Care
10.12. Canada Intravenous Immunoglobulin Market Forecast, by Indication
10.12.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
10.12.2. Primary humoral immunodeficiency
10.12.3. Idiopathic thrombocytopenic purpura (ITP)
10.12.4. Guillain-Barre syndrome
10.12.5. Myasthenia gravis
10.12.6. Multifocal motor neuropathy (MMN)
10.12.7. Kawasaki disease
10.12.8. Hypogammaglobulinemia
10.12.9. Chronic lymphocytic leukemia
10.13. Canada Intravenous Immunoglobulin Market Forecast, by End User
10.13.1. Hospitals
10.13.2. Clinics
10.13.3. Home Care
10.14. North America Intravenous Immunoglobulin Market Attractiveness Analysis
10.14.1. By Indication
10.14.2. By End User
10.15. PEST Analysis
10.16. Key Trends
10.17. Key Development

11. Europe Intravenous Immunoglobulin Market Analysis
11.1. Key Findings
11.2. Europe Intravenous Immunoglobulin Market Overview
11.3. Europe Intravenous Immunoglobulin Market Value Share Analysis, by Indication
11.4. Europe Intravenous Immunoglobulin Market Forecast, by Indication
11.4.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
11.4.2. Primary humoral immunodeficiency
11.4.3. Idiopathic thrombocytopenic purpura (ITP)
11.4.4. Guillain-Barre syndrome
11.4.5. Myasthenia gravis
11.4.6. Multifocal motor neuropathy (MMN)
11.4.7. Kawasaki disease
11.4.8. Hypogammaglobulinemia
11.4.9. Chronic lymphocytic leukemia
11.5. Europe Intravenous Immunoglobulin Market Value Share Analysis, by End User
11.6. Europe Intravenous Immunoglobulin Market Forecast, by End User
11.6.1. Hospitals
11.6.2. Clinics
11.6.3. Home Care
11.7. Europe Intravenous Immunoglobulin Market Value Share Analysis, by Country
11.8. Europe Intravenous Immunoglobulin Market Forecast, by Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Europe Intravenous Immunoglobulin Market Analysis, by Country
11.10. Germany Intravenous Immunoglobulin Market Forecast, by Indication
11.10.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
11.10.2. Primary humoral immunodeficiency
11.10.3. Idiopathic thrombocytopenic purpura (ITP)
11.10.4. Guillain-Barre syndrome
11.10.5. Myasthenia gravis
11.10.6. Multifocal motor neuropathy (MMN)
11.10.7. Kawasaki disease
11.10.8. Hypogammaglobulinemia
11.10.9. Chronic lymphocytic leukemia
11.11. Germany Intravenous Immunoglobulin Market Forecast, by End User
11.11.1. Hospitals
11.11.2. Clinics
11.11.3. Home Care
11.12. U.K. Intravenous Immunoglobulin Market Forecast, by Indication
11.12.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
11.12.2. Primary humoral immunodeficiency
11.12.3. Idiopathic thrombocytopenic purpura (ITP)
11.12.4. Guillain-Barre syndrome
11.12.5. Myasthenia gravis
11.12.6. Multifocal motor neuropathy (MMN)
11.12.7. Kawasaki disease
11.12.8. Hypogammaglobulinemia
11.12.9. Chronic lymphocytic leukemia
11.13. U.K. Intravenous Immunoglobulin Market Forecast, by End User
11.13.1. Hospitals
11.13.2. Clinics
11.13.3. Home Care
11.14. France Intravenous Immunoglobulin Market Forecast, by Indication
11.14.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
11.14.2. Primary humoral immunodeficiency
11.14.3. Idiopathic thrombocytopenic purpura (ITP)
11.14.4. Guillain-Barre syndrome
11.14.5. Myasthenia gravis
11.14.6. Multifocal motor neuropathy (MMN)
11.14.7. Kawasaki disease
11.14.8. Hypogammaglobulinemia
11.14.9. Chronic lymphocytic leukemia
11.15. France Intravenous Immunoglobulin Market Forecast, by End User
11.15.1. Hospitals
11.15.2. Clinics
11.15.3. Home Care
11.16. Italy Intravenous Immunoglobulin Market Forecast, by Indication
11.16.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
11.16.2. Primary humoral immunodeficiency
11.16.3. Idiopathic thrombocytopenic purpura (ITP)
11.16.4. Guillain-Barre syndrome
11.16.5. Myasthenia gravis
11.16.6. Multifocal motor neuropathy (MMN)
11.16.7. Kawasaki disease
11.16.8. Hypogammaglobulinemia
11.16.9. Chronic lymphocytic leukemia
11.17. Italy Intravenous Immunoglobulin Market Forecast, by End User
11.17.1. Hospitals
11.17.2. Clinics
11.17.3. Home Care
11.18. Spain Intravenous Immunoglobulin Market Forecast, by Indication
11.18.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
11.18.2. Primary humoral immunodeficiency
11.18.3. Idiopathic thrombocytopenic purpura (ITP)
11.18.4. Guillain-Barre syndrome
11.18.5. Myasthenia gravis
11.18.6. Multifocal motor neuropathy (MMN)
11.18.7. Kawasaki disease
11.18.8. Hypogammaglobulinemia
11.18.9. Chronic lymphocytic leukemia
11.19. Spain Intravenous Immunoglobulin Market Forecast, by End User
11.19.1. Hospitals
11.19.2. Clinics
11.19.3. Home Care
11.20. Rest of Europe Intravenous Immunoglobulin Market Forecast, by Indication
11.20.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
11.20.2. Primary humoral immunodeficiency
11.20.3. Idiopathic thrombocytopenic purpura (ITP)
11.20.4. Guillain-Barre syndrome
11.20.5. Myasthenia gravis
11.20.6. Multifocal motor neuropathy (MMN)
11.20.7. Kawasaki disease
11.20.8. Hypogammaglobulinemia
11.20.9. Chronic lymphocytic leukemia
11.21. Rest of Europe Intravenous Immunoglobulin Market Forecast, by End User
11.21.1. Hospitals
11.21.2. Clinics
11.21.3. Home Care
11.22. Europe Intravenous Immunoglobulin Market Attractiveness Analysis
11.22.1. By Indication
11.22.2. By End User
11.23. PEST Analysis
11.24. Key Trend
11.25. Key Development

12. Asia Pacific Intravenous Immunoglobulin Market Analysis
12.1. Key Findings
12.2. Asia Pacific Intravenous Immunoglobulin Market Overview
12.3. Asia Pacific Intravenous Immunoglobulin Market Value Share Analysis, by Indication
12.4. Asia Pacific Intravenous Immunoglobulin Market Forecast, by Indication
12.4.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
12.4.2. Primary humoral immunodeficiency
12.4.3. Idiopathic thrombocytopenic purpura (ITP)
12.4.4. Guillain-Barre syndrome
12.4.5. Myasthenia gravis
12.4.6. Multifocal motor neuropathy (MMN)
12.4.7. Kawasaki disease
12.4.8. Hypogammaglobulinemia
12.4.9. Chronic lymphocytic leukemia
12.5. Asia Pacific Intravenous Immunoglobulin Market Value Share Analysis, by End User
12.6. Asia Pacific Intravenous Immunoglobulin Market Forecast, by End User
12.6.1. Hospitals
12.6.2. Clinics
12.6.3. Home Care
12.7. Asia Pacific Intravenous Immunoglobulin Market Value Share Analysis, by Country
12.8. Asia Pacific Intravenous Immunoglobulin Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. ASEAN
12.8.5. Rest of Asia Pacific
12.9. Asia Pacific Intravenous Immunoglobulin Market Analysis, by Country
12.10. China Intravenous Immunoglobulin Market Forecast, by Indication
12.10.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
12.10.2. Primary humoral immunodeficiency
12.10.3. Idiopathic thrombocytopenic purpura (ITP)
12.10.4. Guillain-Barre syndrome
12.10.5. Myasthenia gravis
12.10.6. Multifocal motor neuropathy (MMN)
12.10.7. Kawasaki disease
12.10.8. Hypogammaglobulinemia
12.10.9. Chronic lymphocytic leukemia
12.11. China Intravenous Immunoglobulin Market Forecast, by End User
12.11.1. Hospitals
12.11.2. Clinics
12.11.3. Home Care
12.12. India Intravenous Immunoglobulin Market Forecast, by Indication
12.12.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
12.12.2. Primary humoral immunodeficiency
12.12.3. Idiopathic thrombocytopenic purpura (ITP)
12.12.4. Guillain-Barre syndrome
12.12.5. Myasthenia gravis
12.12.6. Multifocal motor neuropathy (MMN)
12.12.7. Kawasaki disease
12.12.8. Hypogammaglobulinemia
12.12.9. Chronic lymphocytic leukemia
12.13. India Intravenous Immunoglobulin Market Forecast, by End User
12.13.1. Hospitals
12.13.2. Clinics
12.13.3. Home Care
12.14. Japan Intravenous Immunoglobulin Market Forecast, by Indication
12.14.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
12.14.2. Primary humoral immunodeficiency
12.14.3. Idiopathic thrombocytopenic purpura (ITP)
12.14.4. Guillain-Barre syndrome
12.14.5. Myasthenia gravis
12.14.6. Multifocal motor neuropathy (MMN)
12.14.7. Kawasaki disease
12.14.8. Hypogammaglobulinemia
12.14.9. Chronic lymphocytic leukemia
12.15. Japan Intravenous Immunoglobulin Market Forecast, by End User
12.15.1. Hospitals
12.15.2. Clinics
12.15.3. Home Care
12.16. ASEAN Intravenous Immunoglobulin Market Forecast, by Indication
12.16.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
12.16.2. Primary humoral immunodeficiency
12.16.3. Idiopathic thrombocytopenic purpura (ITP)
12.16.4. Guillain-Barre syndrome
12.16.5. Myasthenia gravis
12.16.6. Multifocal motor neuropathy (MMN)
12.16.7. Kawasaki disease
12.16.8. Hypogammaglobulinemia
12.16.9. Chronic lymphocytic leukemia
12.17. ASEAN Intravenous Immunoglobulin Market Forecast, by End User
12.17.1. Hospitals
12.17.2. Clinics
12.17.3. Home Care
12.18. Rest of Asia Pacific Intravenous Immunoglobulin Market Forecast, by Indication
12.18.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
12.18.2. Primary humoral immunodeficiency
12.18.3. Idiopathic thrombocytopenic purpura (ITP)
12.18.4. Guillain-Barre syndrome
12.18.5. Myasthenia gravis
12.18.6. Multifocal motor neuropathy (MMN)
12.18.7. Kawasaki disease
12.18.8. Hypogammaglobulinemia
12.18.9. Chronic lymphocytic leukemia
12.19. Rest of Asia Pacific Intravenous Immunoglobulin Market Forecast, by End User
12.19.1. Hospitals
12.19.2. Clinics
12.19.3. Home Care
12.20. Asia Pacific Intravenous Immunoglobulin Market Attractiveness Analysis
12.20.1. By Indication
12.20.2. By End User
12.21. PEST Analysis
12.22. Key Trend
12.23. Key Development

13. Middle East & Africa Intravenous Immunoglobulin Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Intravenous Immunoglobulin Market Overview
13.3. Middle East & Africa Intravenous Immunoglobulin Market Value Share Analysis, by Indication
13.4. Middle East & Africa Intravenous Immunoglobulin Market Forecast, by Indication
13.4.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
13.4.2. Primary humoral immunodeficiency
13.4.3. Idiopathic thrombocytopenic purpura (ITP)
13.4.4. Guillain-Barre syndrome
13.4.5. Myasthenia gravis
13.4.6. Multifocal motor neuropathy (MMN)
13.4.7. Kawasaki disease
13.4.8. Hypogammaglobulinemia
13.4.9. Chronic lymphocytic leukemia
13.5. Middle East & Africa Intravenous Immunoglobulin Market Value Share Analysis, by End User
13.6. Middle East & Africa Intravenous Immunoglobulin Market Forecast, by End User
13.6.1. Hospitals
13.6.2. Clinics
13.6.3. Home Care
13.7. Middle East & Africa Intravenous Immunoglobulin Market Value Share Analysis, by Country
13.8. Middle East & Africa Intravenous Immunoglobulin Market Forecast, by Country
13.8.1. GCC
13.8.2. South Africa
13.8.3. Rest of Middle East & Africa
13.9. Middle East & Africa Intravenous Immunoglobulin Market Analysis, by Country
13.10. GCC Intravenous Immunoglobulin Market Forecast, by Indication
13.10.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
13.10.2. Primary humoral immunodeficiency
13.10.3. Idiopathic thrombocytopenic purpura (ITP)
13.10.4. Guillain-Barre syndrome
13.10.5. Myasthenia gravis
13.10.6. Multifocal motor neuropathy (MMN)
13.10.7. Kawasaki disease
13.10.8. Hypogammaglobulinemia
13.10.9. Chronic lymphocytic leukemia
13.11. GCC Intravenous Immunoglobulin Market Forecast, by End User
13.11.1. Hospitals
13.11.2. Clinics
13.11.3. Home Care
13.12. South Africa Intravenous Immunoglobulin Market Forecast, by Indication
13.12.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
13.12.2. Primary humoral immunodeficiency
13.12.3. Idiopathic thrombocytopenic purpura (ITP)
13.12.4. Guillain-Barre syndrome
13.12.5. Myasthenia gravis
13.12.6. Multifocal motor neuropathy (MMN)
13.12.7. Kawasaki disease
13.12.8. Hypogammaglobulinemia
13.12.9. Chronic lymphocytic leukemia
13.13. South Africa Intravenous Immunoglobulin Market Forecast, by End User
13.13.1. Hospitals
13.13.2. Clinics
13.13.3. Home Care
13.14. Rest of Middle East & Africa Intravenous Immunoglobulin Market Forecast, by Indication
13.14.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
13.14.2. Primary humoral immunodeficiency
13.14.3. Idiopathic thrombocytopenic purpura (ITP)
13.14.4. Guillain-Barre syndrome
13.14.5. Myasthenia gravis
13.14.6. Multifocal motor neuropathy (MMN)
13.14.7. Kawasaki disease
13.14.8. Hypogammaglobulinemia
13.14.9. Chronic lymphocytic leukemia
13.15. Rest of Middle East & Africa Intravenous Immunoglobulin Market Forecast, by End User
13.15.1. Hospitals
13.15.2. Clinics
13.15.3. Home Care
13.16. Middle East & Africa Intravenous Immunoglobulin Market Attractiveness Analysis
13.16.1. By Indication
13.16.2. By End User
13.17. PEST Analysis
13.18. Key Trend
13.19. Key Development

14. South America Intravenous Immunoglobulin Market Analysis
14.1. Key Findings
14.2. South America Intravenous Immunoglobulin Market Overview
14.3. South America Intravenous Immunoglobulin Market Value Share Analysis, by Indication
14.4. South America Intravenous Immunoglobulin Market Forecast, by Indication
14.4.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
14.4.2. Primary humoral immunodeficiency
14.4.3. Idiopathic thrombocytopenic purpura (ITP)
14.4.4. Guillain-Barre syndrome
14.4.5. Myasthenia gravis
14.4.6. Multifocal motor neuropathy (MMN)
14.4.7. Kawasaki disease
14.4.8. Hypogammaglobulinemia
14.4.9. Chronic lymphocytic leukemia
14.5. Others South America Intravenous Immunoglobulin Market Value Share Analysis, by End User
14.6. South America Intravenous Immunoglobulin Market Forecast, by End User
14.6.1. Hospitals
14.6.2. Clinics
14.6.3. Home Care
14.7. South America Intravenous Immunoglobulin Market Value Share Analysis, by Country
14.8. South America Intravenous Immunoglobulin Market Forecast, by Country
14.8.1. Brazil
14.8.2. Mexico
14.8.3. Rest of South America
14.9. Brazil Intravenous Immunoglobulin Market Forecast, by Indication
14.9.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
14.9.2. Primary humoral immunodeficiency
14.9.3. Idiopathic thrombocytopenic purpura (ITP)
14.9.4. Guillain-Barre syndrome
14.9.5. Myasthenia gravis
14.9.6. Multifocal motor neuropathy (MMN)
14.9.7. Kawasaki disease
14.9.8. Hypogammaglobulinemia
14.9.9. Chronic lymphocytic leukemia
14.10. Brazil Intravenous Immunoglobulin Market Forecast, by End User
14.10.1. Hospitals
14.10.2. Clinics
14.10.3. Home Care
14.11. Mexico Intravenous Immunoglobulin Market Forecast, by Indication
14.11.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
14.11.2. Primary humoral immunodeficiency
14.11.3. Idiopathic thrombocytopenic purpura (ITP)
14.11.4. Guillain-Barre syndrome
14.11.5. Myasthenia gravis
14.11.6. Multifocal motor neuropathy (MMN)
14.11.7. Kawasaki disease
14.11.8. Hypogammaglobulinemia
14.11.9. Chronic lymphocytic leukemia
14.12. Mexico Intravenous Immunoglobulin Market Forecast, by End User
14.12.1. Hospitals
14.12.2. Clinics
14.12.3. Home Care
14.13. Rest of South America Intravenous Immunoglobulin Market Forecast, by Indication
14.13.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP)
14.13.2. Primary humoral immunodeficiency
14.13.3. Idiopathic thrombocytopenic purpura (ITP)
14.13.4. Guillain-Barre syndrome
14.13.5. Myasthenia gravis
14.13.6. Multifocal motor neuropathy (MMN)
14.13.7. Kawasaki disease
14.13.8. Hypogammaglobulinemia
14.13.9. Chronic lymphocytic leukemia
14.14. Rest of South America Intravenous Immunoglobulin Market Forecast, by End User
14.14.1. Hospitals
14.14.2. Clinics
14.14.3. Home Care
14.15. South America Intravenous Immunoglobulin Market Attractiveness Analysis
14.15.1. By Indication
14.15.2. By End User
14.16. PEST Analysis
14.17. Key Trend
14.18. Key Development

15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, End Users and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and End Users
15.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
15.3. Company Profiles: Key Players
15.3.1. Baxter international Inc.
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Company Footprint
15.3.2. CSL Ltd.
15.3.3. Grifols S.A
15.3.4. Octapharma AG
15.3.5. Kedrion Biopharma Inc.
15.3.6. LFB group
15.3.7. Biotest AG
15.3.8. China Biologics Products, Inc.
15.3.9. Takeda Pharmaceuticals
15.3.10. Bayer Healthcare
15.3.11. Hualan Biological Engineering Inc.
15.3.12. Omrix Biopharmaceuticals Ltd.
15.3.13. Behring GmbH
15.3.14. Shanghai RAAS Blood Products Co., Ltd.
15.3.15. Option Care Enterprises, Inc.
15.3.16. ADMA Biologics, Inc.
15.3.17. BioScrip, Inc.
15.3.18. Bio Products Laboratory Limited
15.3.19. ABEONA THERAPEUTICS
15.3.20. BDI Pharma
15.3.21. Biotest AG

16. Primary Key Insights
  • INQUIRE BEFORE BUYING